29,263 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Bought by FORA Capital LLC

FORA Capital LLC purchased a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the 3rd quarter, Holdings Channel.com reports. The firm purchased 29,263 shares of the biopharmaceutical company’s stock, valued at approximately $313,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of FOLD. OLD Second National Bank of Aurora acquired a new stake in Amicus Therapeutics during the 3rd quarter worth $26,000. Hazlett Burt & Watson Inc. raised its stake in Amicus Therapeutics by 156.9% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 1,569 shares in the last quarter. Blue Trust Inc. raised its stake in Amicus Therapeutics by 1,705.4% during the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 2,831 shares in the last quarter. Arcadia Investment Management Corp MI acquired a new stake in Amicus Therapeutics during the 3rd quarter worth $32,000. Finally, Headlands Technologies LLC acquired a new stake in Amicus Therapeutics during the 2nd quarter worth $89,000.

Amicus Therapeutics Stock Up 0.2 %

Shares of NASDAQ:FOLD opened at $9.98 on Friday. The company has a market cap of $2.98 billion, a price-to-earnings ratio of -29.35 and a beta of 0.68. Amicus Therapeutics, Inc. has a fifty-two week low of $9.02 and a fifty-two week high of $14.57. The firm’s 50-day simple moving average is $10.73 and its 200-day simple moving average is $10.58. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18.

Wall Street Analyst Weigh In

Several brokerages recently commented on FOLD. Bank of America lifted their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. raised their price objective on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Guggenheim raised their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Morgan Stanley lowered their price objective on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Finally, StockNews.com raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 16th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $17.63.

Insider Buying and Selling

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,901 shares of Amicus Therapeutics stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total transaction of $98,762.50. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at approximately $11,083,175. The trade was a 0.88 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last 90 days, insiders have sold 30,401 shares of company stock valued at $352,038. Corporate insiders own 2.20% of the company’s stock.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.